Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
Praxis Precision Medicines, Inc. [PRAX]
Reports for Purchase
Showing records 21 - 40 ( 104 total )
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Differentiated Epilepsy Should Shine at Upcoming AES Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Adjusting PT, EPS Estimates Following 1-For-15 Reverse Stock Split
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Competitor''s Recent FOS Phase 2 Failure Validates Praxis'' Approach with ''628; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
With ET Phase 3 Efforts Underway, Focus Remains On Execution [3Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
RD Day Event Shines Light on ET Phase 3 Plans, Early PRAX-222 Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
PRAX-222 Offers a Signal That''s Too Meaningful to Ignore
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Attention shifts to epilepsy portfolio, though opportunity in ET should not be overlooked; we see plenty of potential upside through year-end, with three key catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Our Top Nuggets from HC Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Praxis Remains Overlooked But 2H23 Readouts Offer Opportunity For Re-Rating; PT Adjusted to $7; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
RD Event In October Approaching As Ulixacaltamide To Enter Phase 3 in 4Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data From Two Programs Boost Confidence Into Readouts; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Layering in the Offering As PRAX Advances Ulixacaltamide
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Positive End-of-Phase 2 Meeting With the FDA Brings Clarity to Ulixacaltamide?s Registrational Path
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
On To Phase 3 for Ulixacaltamide in ET, Following End-of-Phase 2 FDA Meeting
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Company Presentations at Tremor Congress 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Readouts Bring Epilepsy Portfolio to Center Stage; Adjusting PT to $15; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D